Wednesday, June 01, 2022 11:02:10 PM
Throw HCT into a phase 2. That’s good for a few years of milk. Pluristem and Tnuva could just keep silent for a few years too. Like UTHR or CHA deals. Won’t even mention the Japanese partner they should have by the end of 2016 as promised. Bring back some GvHD pre-clinical results and start a phase 1. Throw away some more cash and hire another SSCIENTIFIC steering committee on preeclampsia. Who cares if you have to pay them. Some will lap it up like good little minions.
But seriously I could see them getting to half a billion. Only another $150 mil to go. How they’ve made it to $350 mil so far is mind blowing. But raises are the ONLY thing this company does well. All to benefit employees ONLY unfortunately.
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM